Cognition
Semax
ACTH(4-7)-Pro-Gly-Pro
Semax is a synthetic peptide built from a fragment of the hormone ACTH, developed and studied mainly in Russia. It is not FDA-approved, and most of its clinical literature has not been replicated in Western trials.
Key facts
- Commonly discussed for: focus, memory and stroke recovery.
- Evidence (C): Human data come mostly from Russian clinical studies, such as a 2018 study of 110 ischemic-stroke patients comparing rehabilitation with and without Semax. These are small and not large, independently replicated randomized trials.
- FDA status: PCAC recommended. On July 24, 2026 the PCAC voted 8-5 (1 abstention) to recommend Semax for the 503A Bulks List for cerebral ischemia, migraine and trigeminal neuralgia. In a notice published Oct 30, 2026, HHS said it does not intend to take enforcement action against licensed pharmacies and physicians compounding it under set conditions while the FDA writes rules. That is interim enforcement discretion, not FDA approval, and the FDA had not proposed adding it to the list as of Nov 18, 2026.
- Legitimate access: Prescription compounding under an interim HHS policy (not FDA-approved).
- Last reviewed: October 1, 2026.
Read the deep dives
Sources
- Gusev et al. The efficacy of Semax in patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr, 2018
- Effectiveness of Semax in the acute period of hemispheric ischemic stroke. Zh Nevrol Psikhiatr, 1997
- McDermott Will & Schulte: PCAC backs majority of peptides in two-day public meeting (July 2026)
- Federal Register notice of PCAC meeting and uses under review (April 16, 2026)